EMA COVID-19 Vaccine Monitor (CVM): Rapid Safety Assessment of SARS-CoV-2 Vaccines in EU Member States Using Electronic Health Care Datasources
This two-year project was requested by the EMA to extend and build on work from the Early Covid Vaccine Monitor Study (see below) and concluded in April 2023. The Covid Vaccine Monitor project, or CVM, supported COVID-19 vaccine safety monitoring in three ways: firstly by repeatedly asking more than 680,000 vaccinated people directly about side effects, secondly with available pseudonymized electronic health records across Europe to quickly evaluate and quantify associations between adverse events and Covid-19 vaccinations, and thirdly by evaluating methodologies. CVM was conducted in collaboration with the EU Pharmacoepidemiology & Pharmacovigilance Research Network (EU PE&PV) and VAC4EU. See our Outputs page for CVM publications and other deliverables.